Crystalvue Medical Corporation (6527) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Crystalvue Medical Corporation stock TWD 51.00, price TWD 72.10, that is 29.3% below the price, quality 57 out of 100. Rating: overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 34.47 TWD – 106.78 TWD · fair‑value band 39.44 TWD – 55.05 TWD · the 72.10 TWD price screens above the 51.00 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Crystalvue Medical in your weekly email
Every Wednesday you see whether Crystalvue Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Crystalvue Medical Corporation manufactures and sells medical devices worldwide. The company offers optical coherence tomography, retinal cameras, tonometers, lens edgers, and gastroenterology supplies, as well as ODM/OEM services for automated nucleic acid extraction instrument and PCR system.
Show moreShow less
It also sells minimal invasive endoscopic instrument supplies. The company was founded in 2009 and is based in Taoyuan City, Taiwan.
Stock analysis
Crystalvue Medical Corporation (6527) currently trades at 72.10 TWD, while our model-based Fair Value estimate is 51.00 TWD, 29% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 120.80 TWD per share, and 8 of the 16 models we run sit above the 72.10 TWD price.
Bear case: the Asset-Based group reads lowest at 14.76 TWD, and 8 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: 39.44 TWD (bear) to 55.05 TWD (bull), the price of 72.10 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Crystalvue Medical Corporation reported revenue of 949M TWD in FY2025 versus 722M TWD in FY2021, a compound +7.1%/yr. Reported net income was 147M TWD in FY2025, compounding +17.5%/yr from FY2021.
Key figures
Market cap 1.8B TWD (≈ $55.7M) Micro · P/E ratio 12.5 · P/S ratio 2.09 · EPS (TTM) 5.76 TWD · Dividend yield 4.0% · Net margin 17.0% · Return on equity 15.0% · Return on assets (EBIT) 11.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 68 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 13% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −29%, 6527 screens cheaper than that median.
Fair Value models
Bear39.44 TWDFair Value 51.00 TWDBull55.05 TWD
Price 72.10 TWD · Downside -29.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2.45 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+17.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.5%
Dividend (yield on the price)4.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 19%
Compare Crystalvue Medical Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Below median
Fair Value upside−29.3% · Below median
Profitability
Return on equity (12 months)15.0% · Top 25%
Return on assets11.4% · Top 25%
Net margin (12 months)17.0% · Top 25%
Operating margin (12 months)21.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−15.1% · Bottom 25%
Dividend yield (12 months)4.0% · Top 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)12.5× · Cheapest 25%
P/B1.78× · Cheaper than median
P/S (12 months)2.09× · Cheaper than median
EV/EBITDA9.9× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)0· sector 40
PAST (return on equity)60· sector 30
HEALTH (low debt)0· sector 96
DIVIDEND (yield)80· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Crystalvue Medical Corporation Fair Value". https://www.fairvalue-calculator.com/stock/6527
Frequently asked questions
Is Crystalvue Medical Corporation (6527) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 51.00 TWD versus a price of 72.10 TWD, about 29% lower (overvalued).
What is the fair value of 6527?
Our model-based fair value for Crystalvue Medical Corporation is 51.00 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 72.10 TWD.
What is the quality score of 6527?
Crystalvue Medical Corporation has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Crystalvue Medical Corporation (6527)?
Our model-based price target is the fair value of 51.00 TWD (as of Nov 9, 2026) from 16 valuation models. Cautious scenario 39.44 TWD, optimistic scenario 55.05 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Crystalvue Medical Corporation stock forecast for 2026?
Our models put fair value at 51.00 TWD, about 29% lower versus a price of 72.10 TWD (overvalued). Cautious scenario 39.44 TWD, optimistic scenario 55.05 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Crystalvue Medical Corporation (6527)?
Crystalvue Medical Corporation reported trailing-twelve-month revenue of about 874M TWD (latest available figure, as of Nov 9, 2026).
Does Crystalvue Medical Corporation pay a dividend?
Crystalvue Medical Corporation currently shows a dividend yield of 4.02% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Crystalvue Medical Corporation (6527) and when is the ex-dividend date?
Crystalvue Medical Corporation pays a dividend of 2.90 TWD per share a year, a dividend yield of 4.0%. The last ex-dividend date was Jul 21, 2026. A dividend has been paid every year since at least 2015. The payout ratio is 50.3% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Crystalvue Medical Corporation (6527)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Crystalvue Medical Corporation it is 51.00 TWD per share (as of Nov 9, 2026), against a price of 72.10 TWD. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Crystalvue Medical Corporation stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6527 trades above its calculated fair value: price 72.10 TWD, fair value 51.00 TWD, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6527?
No. The price is what the market pays today (72.10 TWD); the fair value is what the company's own numbers justify (51.00 TWD). For Crystalvue Medical Corporation the two are 21.10 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Crystalvue Medical Corporation worth?
The market values Crystalvue Medical Corporation at about 1.8B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 72.10 TWD; our models calculate a fair value of 51.00 TWD per share.
What do the bullish and bearish scenarios say about 6527?
Our models span a range for Crystalvue Medical Corporation: cautious scenario 39.44 TWD, base 51.00 TWD, optimistic 55.05 TWD per share (as of Nov 9, 2026, price 72.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6527?
Crystalvue Medical Corporation trades at a price-to-earnings ratio of 12.5 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 51.00 TWD is built from several models across several years. Other multiples: P/B 1.8, P/S 2.1, EV/EBITDA 9.9.
How solid is the balance sheet of Crystalvue Medical Corporation (6527)?
Balance-sheet figures for Crystalvue Medical Corporation (as of Nov 9, 2026): return on equity 15.0%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 6527 from its 52-week high?
Crystalvue Medical Corporation trades at 72.10 TWD, about 9% below its 52-week high of 79.29 TWD and 13% above the low of 64.05 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 51.00 TWD is for.
Which stocks are comparable to Crystalvue Medical Corporation?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Crystalvue Medical Corporation stock attractive at the current price?
The data as of Nov 9, 2026: price 72.10 TWD, calculated fair value 51.00 TWD (−29%), Quality Score 57/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6527 calculated?
We run Crystalvue Medical Corporation through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 51.00 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Crystalvue Medical Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Crystalvue Medical Corporation (6527)?
The closing price on Nov 6, 2026 was 72.10 TWD. Our model-based fair value is 51.00 TWD, about 29% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Crystalvue Medical Corporation right now?
The price sits above even our optimistic bull case (55.05 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Crystalvue Medical Corporation
How large is the market capitalisation of Crystalvue Medical Corporation (6527)?
The market capitalisation of Crystalvue Medical Corporation is 1.8B TWD (≈ $55.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Crystalvue Medical Corporation (6527)?
The price-to-sales ratio of Crystalvue Medical Corporation is 2.09 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Crystalvue Medical Corporation (6527)?
Earnings per share at Crystalvue Medical Corporation are 5.76 TWD (price ÷ EPS = P/E 12.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Crystalvue Medical Corporation (6527)?
The dividend yield of Crystalvue Medical Corporation is 4.0% (payout 50.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Crystalvue Medical Corporation (6527)?
The net margin of Crystalvue Medical Corporation is 17.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Crystalvue Medical Corporation (6527)?
The return on equity (ROE) of Crystalvue Medical Corporation is 15.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Crystalvue Medical Corporation (6527)?
On an EBIT basis the return on assets of Crystalvue Medical Corporation is 11.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Crystalvue Medical Corporation (6527)?
The operating margin of Crystalvue Medical Corporation is 21.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Crystalvue Medical Corporation (6527)?
Revenue at Crystalvue Medical Corporation is growing −15.1% versus a year earlier (3y avg +6.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Crystalvue Medical Corporation (6527)?
Earnings per share at Crystalvue Medical Corporation are growing +12.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Crystalvue Medical Corporation (6527) generate?
The free cash flow of Crystalvue Medical Corporation is −46.1M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Crystalvue Medical Corporation in the live analysis
One click puts Crystalvue Medical Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026